GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » Shiller PE Ratio

WAVE Life Sciences (STU:1U5) Shiller PE Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


WAVE Life Sciences Shiller PE Ratio Historical Data

The historical data trend for WAVE Life Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Shiller PE Ratio Chart

WAVE Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

WAVE Life Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of WAVE Life Sciences's Shiller PE Ratio

For the Biotechnology subindustry, WAVE Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Shiller PE Ratio falls into.



WAVE Life Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

WAVE Life Sciences's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, WAVE Life Sciences's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.423/133.0289*133.0289
=-0.423

Current CPI (Sep. 2024) = 133.0289.

WAVE Life Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.068 99.070 -0.091
201503 -0.153 99.621 -0.204
201506 -0.157 100.684 -0.207
201509 -0.225 100.392 -0.298
201512 -0.302 99.792 -0.403
201603 -0.323 100.470 -0.428
201606 -0.454 101.688 -0.594
201609 -0.668 101.861 -0.872
201612 -0.758 101.863 -0.990
201703 -0.841 102.862 -1.088
201706 -0.810 103.349 -1.043
201709 -0.772 104.136 -0.986
201712 -0.946 104.011 -1.210
201803 -1.022 105.290 -1.291
201806 -1.053 106.317 -1.318
201809 -1.097 106.507 -1.370
201812 -1.125 105.998 -1.412
201903 -1.204 107.251 -1.493
201906 -1.080 108.070 -1.329
201909 -1.344 108.329 -1.650
201912 -1.485 108.420 -1.822
202003 -1.249 108.902 -1.526
202006 -1.021 108.767 -1.249
202009 -0.730 109.815 -0.884
202012 -0.485 109.897 -0.587
202103 -0.722 111.754 -0.859
202106 -0.647 114.631 -0.751
202109 -0.102 115.734 -0.117
202112 -0.540 117.630 -0.611
202203 -0.563 121.301 -0.617
202206 -0.587 125.017 -0.625
202209 -0.424 125.227 -0.450
202212 -0.444 125.222 -0.472
202303 -0.252 127.348 -0.263
202306 -0.185 128.729 -0.191
202309 0.066 129.860 0.068
202312 -0.138 129.419 -0.142
202403 -0.221 131.776 -0.223
202406 -0.232 132.554 -0.233
202409 -0.423 133.029 -0.423

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


WAVE Life Sciences  (STU:1U5) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


WAVE Life Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences Business Description

Traded in Other Exchanges
Address
Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines